Proteon Therapeutics

Proteon Therapeutics, Inc. is developing PRT-201, an investigational drug intended to address vascular access failure, one of the most serious problems facing hemodialysis patients. The Company has completed a Phase 2 clinical trial evaluating PRT-201 in patients with chronic kidney disease undergoing surgical placement of an arteriovenous fistula (AVF), the optimal form of hemodialysis vascular access. PRT-201 has received FDA fast track and orphan drug designation in hemodialysis vascular access indications.
 
PRT-201 is a locally-acting recombinant human elastase delivered to the external surface of the artery and vein during surgical creation of an AVF. A single treatment of PRT-201 may increase the longevity of an AVF by reducing neointimal hyperplasia, the growth of tissues inside blood vessels that results in vessel narrowing and reduced blood flow.